Abcellera Biologics Inc
NASDAQ:ABCL
Intrinsic Value
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. [ Read More ]
The intrinsic value of one ABCL stock under the Base Case scenario is 2 USD. Compared to the current market price of 3.63 USD, Abcellera Biologics Inc is Overvalued by 45%.
Valuation Backtest
Abcellera Biologics Inc
Run backtest to discover the historical profit from buying and selling ABCL stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Abcellera Biologics Inc
Current Assets | 872m |
Cash & Short-Term Investments | 760.6m |
Receivables | 64.4m |
Other Current Assets | 47m |
Non-Current Assets | 616.1m |
Long-Term Investments | 65.9m |
PP&E | 287.7m |
Intangibles | 168.2m |
Other Non-Current Assets | 94.2m |
Current Liabilities | 119m |
Accounts Payable | 25.5m |
Accrued Liabilities | 13.9m |
Other Current Liabilities | 79.6m |
Non-Current Liabilities | 216.8m |
Other Non-Current Liabilities | 216.8m |
Earnings Waterfall
Abcellera Biologics Inc
Revenue
|
38m
USD
|
Operating Expenses
|
-275.2m
USD
|
Operating Income
|
-237.2m
USD
|
Other Expenses
|
90.8m
USD
|
Net Income
|
-146.4m
USD
|
Free Cash Flow Analysis
Abcellera Biologics Inc
ABCL Profitability Score
Profitability Due Diligence
Abcellera Biologics Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
Abcellera Biologics Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
ABCL Solvency Score
Solvency Due Diligence
Abcellera Biologics Inc's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Score
Abcellera Biologics Inc's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ABCL Price Targets Summary
Abcellera Biologics Inc
According to Wall Street analysts, the average 1-year price target for ABCL is 15.68 USD with a low forecast of 8.08 USD and a high forecast of 29.4 USD.
Ownership
ABCL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ABCL Price
Abcellera Biologics Inc
Average Annual Return | -43.45% |
Standard Deviation of Annual Returns | 17.66% |
Max Drawdown | -94% |
Market Capitalization | 1.1B USD |
Shares Outstanding | 290 046 280 |
Percentage of Shares Shorted | 11.18% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 386 full-time employees. The company went IPO on 2020-12-11. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.
Contact
IPO
Employees
Officers
The intrinsic value of one ABCL stock under the Base Case scenario is 2 USD.
Compared to the current market price of 3.63 USD, Abcellera Biologics Inc is Overvalued by 45%.